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Candidemia studies have documented geographic differences in rates and epidemiology, underscoring the
need for surveillance to monitor trends. We conducted prospective candidemia surveillance in Brazil to assess
the incidence, species distribution, frequency of antifungal resistance, and risk factors for fluconazole-resistant
Candida species. Prospective laboratory-based surveillance was conducted from March 2003 to December 2004
in 11 medical centers located in 9 major Brazilian cities. A case of candidemia was defined as the isolation of
Candida spp. from a blood culture. Incidence rates were calculated per 1,000 admissions and 1,000 patient-
days. Antifungal susceptibility tests were performed by using the broth microdilution assay, according to the
Clinical and Laboratory Standards Institute guidelines. We detected 712 cases, for an overall incidence of 2.49
cases per 1,000 admissions and 0.37 cases per 1,000 patient-days. The 30-day crude mortality was 54%. C.
albicans was the most common species (40.9%), followed by C. tropicalis (20.9%) and C. parapsilosis (20.5%).
Overall, decreased susceptibility to fluconazole occurred in 33 (5%) of incident isolates, 6 (1%) of which were
resistant. There was a linear correlation between fluconazole and voriconazole MICs (r  0.54 and P < 0.001
[Spearman’s rho]). This is the largest multicenter candidemia study conducted in Latin America and shows
the substantial morbidity and mortality of candidemia in Brazil. Antifungal resistance was rare, but correla-
tion between fluconazole and voriconazole MICs suggests cross-resistance may occur.
There is mounting evidence suggesting that Candida blood-
stream infections (BSI) have become a major problem in ter-
tiary-care hospitals worldwide (3, 6, 11, 26, 28, 37, 50). Candi-
demia has been observed particularly among patients
hospitalized for long periods who have been exposed to anti-
biotics, immunosuppressive therapy, parenteral nutrition, and
multiple invasive medical procedures (9, 15). Candidemia is
generally difficult to diagnose and hard to treat, has a high
attributable mortality rate, and is costly (18, 32, 55).
Although the incidence of candidemia among hospitalized
patients increased during the 1980s (8), more-recent reports
suggest that the incidence has stabilized (31). However, can-
didemia rates vary geographically. In The Netherlands, the
incidence of Candida BSI doubled between 1987 and 1995
(53). Likewise, an increasing incidence of candidemia in Ice-
land has been observed during the period between 1980 and
1999 (6). On the other hand, data obtained from a national
surveillance study conducted in Swiss tertiary-care hospitals
suggested that the incidence of candidemia remained un-
changed during the period of 1991 to 2000 (28), while a single-
center study from Switzerland reported decreasing incidence
rates (16). It seems therefore that differences do exist in the
epidemiology of candidemia between different countries, un-
derscoring the need for continuous surveillance to monitor
trends in incidence, species distribution, and antifungal drug
susceptibility profiles.
The epidemiology of candidemia has been extensively stud-
ied in the United States and Europe but not in Latin America.
Data on candidemia in this region are limited to retrospective
reviews of medical records or observational studies conducted
in a limited number of medical centers (5, 11, 12, 46). Conse-
quently, the incidence of candidemia in tertiary-care hospitals
in Brazil is largely unknown, and no national data are avail-
able.
We conducted a prospective laboratory-based surveillance
study in 11 tertiary care hospitals, representative of the public
health system of 9 of the largest cities in Brazil, to assess the
incidence, species distribution, frequency of antifungal resis-
tance, and risk factors for candidemia due to fluconazole-
resistant Candida species.
MATERIALS AND METHODS
Surveillance. We performed prospective laboratory-based surveillance from
March 2003 to December 2004 in 11 tertiary-care academic medical centers
located in 9 cities of the south, southeast, and central regions of Brazil. All
hospitals had automated blood culture systems (BACTEC or BacT-ALERT) and
provide medical care to adults and children in different medical specialties. The
protocol was approved by the local institutional review board of each site.
Case definitions. A case of candidemia was defined as the incident isolation of
Candida spp. from a blood culture. Candidemia occurring 30 days after the
incident isolation was defined as a new case. Breakthrough candidemia was
defined as the incident isolation of Candida spp. from a blood culture from a
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patient receiving systemic antifungal therapy for any reason. Fever was defined
as a temperature of 37.8°C, hypotension as systolic blood pressure of 90 mm
Hg, and neutropenia as an absolute neutrophil count of 500/mm3. Patients
were considered adults if their age was 13 years.
Case accrual. In each center, an investigator was specifically trained to have
daily contact with the microbiology laboratory of the hospital and search for
positive blood cultures. When a candidemia case was identified, clinical and
epidemiological data were prospectively collected in a standardized case report
form.
The case report form contained the following information: age, gender, date of
admission, ward, date of candidemia, underlying medical conditions, exposure to
invasive medical procedures, use of antibiotics or corticosteroids, management of
candidemia (antifungal treatment, catheter removal), and outcome. Audits of hos-
pital laboratories were performed periodically to ensure that no cases of candidemia
were missed. In addition, audits of medical records were performed on 10% of cases
to verify accuracy of data and completeness.
Yeast identification. All Candida species recovered from blood cultures were
sent to the Special Mycology Laboratory at Universidade Federal de Sa˜o Paulo
for confirmation of species identification and performance of antifungal agent
susceptibility tests. Isolates were identified according to their microscopic mor-
phology on cornmeal Tween 80 agar and by biochemical tests using the ID 32C
system (BioMe´rieux AS, Marcy l’Etoile, France). A sample of 30% of all isolates
was sent to the Centers for Disease Control and Prevention, Atlanta, GA, as part
of a quality control program to confirm the identification.
In vitro susceptibility testing. Antifungal susceptibility tests were performed
by using the broth microdilution assay according to the methodology recom-
mended by the CLSI (formerly known as NCCLS), document M27-A2 (33). The
following antifungal drugs, supplied by the manufacturers as pure standard
compounds, were tested at the indicated concentration range: amphotericin B,
0.015 to 8 g/ml (Sigma Chemical Corporation, St. Louis, MO); flucytosine,
0.125 to 64 g/ml (Sigma Chemical Corporation, St. Louis, MO); itraconazole,
0.03 to 16 g/ml (Janssen Pharmaceutical, Titusville, NJ); fluconazole, 0.125 to
64 g/ml; and voriconazole, 0.03 to 16 g/ml (Pfizer Incorporated, New York,
N.Y.). Briefly, the medium used was RPMI-1640, with L-glutamine, without
bicarbonate, and buffered at pH 7.0 with 0.165 M morpholinepropanesulfonic
acid. The yeast inoculum suspension was prepared by using a spectrophotometer
to obtain a final yeast concentration of 0.5 103 to 2.5 103 cells/ml in each well
of the microtiter plate. The assays were incubated at 35°C for 48 h. Quality-
control strains (C. parapsilosis ATCC 22019 and C. krusei ATCC 6258; American
Type Culture Collection, Manassas, VA) were included on each day of assay to
check the accuracy of the drug dilutions and the reproducibility of the results.
The MIC endpoint for amphotericin B was considered the lowest tested drug
concentration able to prevent any visible growth. The MIC for azoles and flucy-
tosine was considered the lowest tested drug concentration causing a significant
reduction (approximately 50%) in growth compared to the growth of the drug-
free positive control (33).
The interpretative MIC breakpoints for azoles and flucytosine were those
suggested by the CLSI document M27-A2. Due to a lack of consensus about the
definition of MIC breakpoints for amphotericin B, arbitrary values suggested in
a previous study were used (34). Isolates with MICs of 8 g/ml for fluconazole,
0.125 g/ml for itraconazole, 1 g/ml for voriconazole, 4 g/ml for flucy-
tosine, and 1 g/ml for amphotericin B were considered susceptible. Isolates
with MICs of 16 and 32 g/ml for fluconazole, 0.25 and 0.5 g/ml for itracon-
azole, and 2 g/ml for voriconazole were considered susceptible in a dose-
dependent manner (SDD). Isolates with MICs of 8 and 16 g/ml were classified
as intermediate to flucytosine. Isolates with MICs of 64 g/ml for fluconazole,
1 g/ml for itraconazole,4 g/ml for voriconazole,32 g/ml for flucytosine,
and2 g/ml for amphotericin B were considered resistant. A sample of 30% of
all isolates, as well as all strains resistant to any antifungal drug, was sent to the
Centers for Disease Control and Prevention, Atlanta, GA, to confirm the accu-
racy of the susceptibility test results.
Statistical analysis. To calculate incidence rates, the numbers of admissions
and patient-days were collected. Incidence rates were calculated as the number
of candidemias per 1,000 admissions and 1,000 patient-days. The overall inci-
dence was determined using summed denominators of patient-days and admis-
sions to calculate pooled mean rates. In addition, during 16 months of the
surveillance, data on the number of BSI caused by different microorganisms
(including bacteria and fungi) were collected from eight centers in order to
estimate the relative burden of candidemia as the etiologic agent of BSIs.
Data were entered by using a web-based case report form, using the SPSS
Enterprise Server 3.0 and SPSS Data Entry Builder 3.03 (SPSS, Inc. Chicago,
IL). Categorical data were analyzed using Chi-square or Fisher’s exact tests, as
appropriate, and continuous variables were compared using the Wilcoxon test.
Spearman rank-order correlation was used to measure the relationship between
the MICs of fluconazole and voriconazole. We performed univariate and mul-
tivariate analysis of factors associated with candidemia caused by less-flucon-
azole-susceptible isolates. Variables significant at P values of 0.1 by univariate
analysis were included in a multivariate model (backward and forward). Data
were analyzed using the SPSS 11.0.1 software (SPSS, Inc. Chicago, IL).
RESULTS
Incidence and demographics. We detected a total of 712
cases of candidemia during the surveillance study, for an over-
all incidence of 2.49 cases per 1,000 admissions and 0.37 cases
per 1,000 patient-days. As illustrated in Fig. 1, the incidence
rate of candidemia in the 11 centers ranged from 1.49 to 5.30
cases per 1,000 admissions and 0.20 to 0.52 cases per 1,000
patient-days. Demographic and clinical characteristics and out-
comes of 712 candidemia cases identified in the surveillance
are shown in Table 1. Males comprised 56% of the case pa-
tients, and the median age was 41 years (range, 0 to 96 years).
Of note, 225 case patients (32%) were children, and 147 (21%)
were younger than 1 year old. The median age was 57 years
among adult patients and 7 months among children.
Candida spp. comprised the fourth-most-frequently isolated
pathogen from blood cultures, preceded by coagulase-negative
staphylococci (11.97 episodes per 1,000 admissions and 1.62
episodes per 1,000 patient-days), Staphylococcus aureus (7.31
per 1,000 admissions and 0.99 per 1,000 patient-days), and
Klebsiella pneumoniae (2.92 per 1,000 admissions and 0.40 per
1,000 patient-days).
Coexisting exposures and underlying diseases. At the time
of the diagnosis of candidemia, 693 case patients (97%) were
FIG. 1. Incidence rates of candidemia among the 11 medical centers.
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hospitalized, including 317 (46%) admitted in the intensive
care unit (ICU) (including the neonatal intensive care unit),
161 (23%) in the medical ward, 101 (15%) in the surgical ward,
74 (11%) in the pediatrics ward, and 40 (6%) in other wards.
Sixteen case-patients were outpatients, and in 3 cases no in-
formation was available. Cancer was documented for 195 case
patients (27%), 75 of which (38%) were hematologic malig-
nancies (Table 1). A total of 281 case patients (39%) had had
prior surgery in the 30 days before candidemia, 180 of which
(64%) were abdominal. A total of 274 case patients (38%)
were on mechanical ventilation at the time of candidemia, 84
(12%) were receiving dialysis, 150 (21%) were receiving par-
enteral nutrition, and 497 (70%) had a central venous catheter.
Neutropenia was present in only 44 case patients (6%). Can-
didemia was generally a late complication during hospital stay,
occurring at a median of 19.5 days after admission (range, 0 to
385). A bacteremia was diagnosed on the same day of candi-
demia for 68 case patients (10%) and within 14 days of candi-
demia for 146 case patients (20%).
Excluding the 91 neonates (40% of the pediatric cases), most
of the children with candidemia had cancer (31%), neurologic
disease (22%), or lung disease (22%). Of the pediatric case
patients, 36% had had surgery in the 30 days prior to the
candidemia, 41% of the case patients were in the ICU, 25%
were on mechanical ventilation, and 14% were receiving par-
enteral nutrition.
Clinical manifestations of candidemia. Fever was the most
frequent clinical manifestation of candidemia, occurring in 419
(62%) of the 678 case patients for which data were available.
Hypotension was reported in 43 (7%) of 620 cases. Deep-
seated Candida infection was documented in only 17 cases
(2%). The presentations of deep-seated candidiasis were en-
docarditis (eight cases), endopthalmitis (five cases), dissemi-
nated candidiasis with skin lesions (two cases), and peritonitis
and chronic disseminated candidiasis (one case each).
Therapy and outcome. At the time of candidemia, 122 case
patients (17%) were receiving a systemic antifungal agent and
were considered breakthrough infections (fluconazole, 80 pa-
tients, 11%; amphotericin B, 36 patients, 5%; itraconazole and
voriconazole, 1 patient each; and other antifungals, 4 patients).
A total of 536 case patients (75%) received antifungal ther-
apy, started at a median of 3 days from the Candida isolation
or onset of candidemia (range, 0 to 27). Excluding the 133 case
patients (19%) who died within 3 days from incident candi-
TABLE 1. Demographics, clinical characteristics, and outcomes for candidemic episodes identified during
prospective sentinel surveillance conducted in Brazil in 2003 and 2004
Variable Value for allcasesb
Value for speciesc,d
C. albicans C. tropicalis C. parapsilosis C. glabrata
Median agee (range) 41 (0–96) 46 (0–92) 48 (0–96) 33 (0–89) 52 (0–88)
No. of males 400 (56) 168 (58) 83 (56) 86 (59) 18 (51)
Age of 1 yr 147 (21) 63 (22) 18 (12)* 30 (20) 5 (14)
No. of outpatients 16 (2) 5 (2) 2 (1) 6 (4) 1 (3)
Median no. of days (range) in hospital until candidemia 20 (0–385) 20 (0–114) 19 (0–385) 19 (0–47) 19 (0–115)
No. of cases of underlying diseases
Cancer 195 (27) 66 (23) 47 (32)* 39 (27) 12 (34)
Hematologic malignancy 75 (10) 25 (9) 19 (13) 16 (11) 4 (11)
Cardiac disease 139 (19) 53 (18) 32 (22) 34 (23) 7 (20)
Pulmonary disease 138 (19) 63 (22) 29 (19) 24 (16) 5 (14)
Liver disease 56 (8) 21 (7) 16 (11) 6 (4) 5 (14)
Neurologic disease 120 (17) 54 (19) 27 (18) 24 (16) 3 (9)
Diabetes 93 (13) 42 (14) 21 (14) 20 (14) 6 (17)
Renal insufficiency 138 (19) 56 (19) 25 (17) 35 (24) 11 (31)
Organ transplant 14 (2) 3 (1) 1 (1) 4 (3) 1 (3)
HIVa infection 22 (3) 8 (3) 6 (4) 5 (3) 1 (3)
No. of patients with characteristic
Use of corticosteroids 228 (32) 100 (34) 48 (32) 36 (25)* 10 (29)
Neutropenia 44 (6) 10 (3) 12 (8)* 10 (7) 2 (6)
In the ICU at diagnosis 317 (44) 127 (44) 66 (44) 63 (43) 15 (43)
Mechanical ventilation 274 (38) 119 (41) 55 (37) 45 (31)* 18 (51)
Dialysis 84 (12) 37 (13) 20 (13) 20 (14) 3 (9)
Previous Candida colonization 114 (16) 56 (19) 26 (17) 19 (13) 7 (20)
Previous surgery 281 (39) 128 (44) 52 (35) 52 (36) 18 (51)
Abdominal surgery 180 (25) 82 (28) 31 (21) 34 (23) 14 (40)
Central venous catheter 497 (70) 216 (74) 104 (70) 96 (66) 31 (89)
Parenteral nutrition 150 (21) 61 (21) 32 (22) 34 (23) 8 (23)
Prior antibiotic therapy 669 (94) 277 (95) 141 (95) 132 (90) 33 (94)
Prior fluconazole use 80 (11) 29 (10) 10 (7) 14 (10) 9 (26)*
Death by day 7 of candidemia 221 (31) 98 (34) 49 (33) 32 (22)* 15 (43)
Overall mortality 383 (54) 166 (57) 91 (61) 66 (45)* 24 (69)
a HIV, human immunodeficiency virus.
b A total of 712 cases were studied. Values in parentheses are percentages unless specified differently.
c Values in parentheses are percentages unless specified differently. Numbers of cases are as follows: for C. albicans, 291; for C. tropicalis, 149; for C. parapsilosis,
146; for C. glabrata, 35.
d , value is significantly different (P  0.05) from that for C. albicans.
e Ages are given in years.
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demia, 86% of case patients (492 of 574) received treatment.
Amphotericin B was the most frequently used drug as primary
treatment (274 cases; 38%), followed by fluconazole (224
cases; 32%). Twenty-seven case patients received antifungal
treatment as part of a double-blind randomized trial compar-
ing an echinocandin to a lipid formulation of amphotericin B.
Other drugs used as primary treatment were the following: a
lipid formulation of amphotericin B (five cases), caspofungin
(four cases), voriconazole (two cases), and unknown (five
cases). For 22% of the 492 case patients that received treat-
ment, the initial antifungal drug was changed after a median of
5 days of treatment. The most frequent change was the sub-
stitution of fluconazole for deoxycholate amphotericin B (47
cases) and amphotericin B for fluconazole (32 cases). The
median duration of treatment was 14 days (range, 1 to 70).
The 3-day, 7-day, and 30-day mortality rates were 19%, 31%,
and 54%, respectively. The 30-day mortality rate among chil-
dren 1 year old was 43%, compared to 23% for children with
ages between 1 and 12 years and 63% for adults (P  0.001).
Candidemia due to C. parapsilosis was associated with a lower
mortality rate than that due to C. albicans (45% versus 57%;
P  0.02).
Species distribution and antifungal susceptibility testing.
Table 2 shows the species distribution. C. albicans was the most
common species (291 cases; 41%), followed by C. tropicalis
(149 cases; 21%) and C. parapsilosis (146 cases; 21%). C.
glabrata comprised only 5% of cases. Among adult cases, the
most common species was C. albicans (199 cases; 41%), followed
by C. tropicalis (114; 24%) and C. parapsilosis (99; 21%). Among
pediatric cases, the most common species was C. albicans (89
cases; 40% of total), followed by C. parapsilosis (47 cases; 21%),
and C. tropicalis and C. pelliculosa (34 cases each; 15%).
Species distribution varied substantially between centers.
The proportion of cases due to C. albicans ranged between 27
and 54%, between 16 and 29% for C. tropicalis, between 7 and
40% for C. parapsilosis, between 2 and 11% for C. glabrata, and
between 0 and 41% for C. pelliculosa. The incidence of candi-
demia due to the different species was as follows (per 1,000
admissions and per 1,000 patient-days): C. albicans, 1.01 and
0.15; C. tropicalis, 0.52 and 0.07; C. parapsilosis, 0.51 and 0.07;
C. glabrata, 0.12 and 0.02; and C. pelliculosa, 0.03 and 0.004
(Table 2).
Compared with candidemia due to C. albicans, candidemia
due to C. tropicalis was less likely to occur among children 1
year old (12% versus 22%; P  0.01) and more likely to occur
in patients with cancer (32% versus 23%; P  0.04) or neu-
tropenia (8% versus 3%; P  0.02). Compared with those due
to C. albicans, cases due to C. parapsilosis were less likely
among patients on mechanical ventilation (31% versus 41%;
P  0.03) or receiving corticosteroids (25% versus 34%; P 
0.04). Case patients receiving fluconazole before developing
candidemia were more likely to be infected by C. glabrata than
C. albicans (26% versus 10%; P  0.008) (Table 1).
Table 3 shows the MIC ranges, MICs at which 50% or 90%
of organisms were inhibited, and percentages of Candida iso-
lates with decreased susceptibilities to the five antifungal drugs
tested. Overall, decreased susceptibility to antifungal agents
was rare. Fluconazole resistance occurred in 6 (0.8%) isolates,
including 1 isolate of C. albicans, 2 of C. glabrata, and 3 of C.
krusei; 27 cases (4%) were classified as SDD to fluconazole (1
case of C. albicans, 15 of C. glabrata, 5 of C. krusei, 2 of C.
tropicalis, 2 of C. guilliermondii, 1 of C. pelliculosa, and 1 of
Pichia ohmeri). One Candida albicans isolate exhibited a MIC
of 4 g/ml to voriconazole; this C. albicans isolate was also
resistant to fluconazole. In addition, one C. glabrata isolate that
was resistant to fluconazole had a voriconazole MIC of 2 g/
ml. Overall, for each isolate, there was a linear correlation
between fluconazole and voriconazole MICs (r  0.54; P 
0.001). In addition, cases that had received fluconazole before
candidemia had somewhat higher voriconazole MICs than
those without previous exposure to fluconazole (MIC90s of
0.25 g/ml and 0.06 g/ml, respectively; P  0.056).
Compared to the case with susceptible isolates, candidemia
caused by an isolate with decreased susceptibility to flucon-
azole (SDD or resistant) was associated with malignancy (9%
versus 3%; P  0.001), previous (11% versus 4%; P  0.02) or
current (16% versus 4%; P  0.001) neutropenia, and prior
fluconazole use (14% versus 3%; P  0.001). By multivariate
analysis, independent factors associated with candidemia due
to an isolate with decreased susceptibility to fluconazole were
malignancy (odds ratio, 2.9; 95% confidence interval, 1.4 to
5.9; P  0.005) and prior use of fluconazole (odds ratio, 3.8;
95% confidence interval, 1.7 to 8.2; P  0.001). Among pa-
tients who received fluconazole as treatment for the candi-
demia, the death rate of patients infected by a susceptible
isolate or a less-susceptible isolate (SDD or resistant) was 54%
or 64%, respectively (P  0.44).
DISCUSSION
This prospective candidemia surveillance represents the
largest multicenter study conducted in Latin America and re-
veals for the first time the large burden of candidemia in
Brazilian tertiary-care hospitals. In addition, it provides the
most representative and consistent data from South America
on the epidemiology of candidemia to date (5, 11, 12, 39).
The first remarkable finding of our study was the high inci-
dence of candidemia. Our rates of 2.49 cases per 1,000 admis-
sions and 0.37 episodes per 1,000 patient-days are 2 to 15 times
higher than those reported for centers in the Northern Hemi-
sphere, including the United States (0.28 to 0.96 per 1,000
admissions) (7, 21, 41, 57), Canada (0.45 per 1,000 admissions)
(27), Europe (0.20 to 0.38 per 1,000 admissions) (50), France
TABLE 2. Species distribution and incidence among 712 cases of
candidemia detected during prospective sentinel
surveillance in Brazil in 2003 and 2004
Species No. (%) ofcases
Incidence per
1,000 admissions
Incidence per
1,000 patient-days
C. albicans 291 (40.9) 1.01 0.15
C. tropicalis 149 (20.9) 0.52 0.07
C. parapsilosis 146 (20.5) 0.51 0.07
C. pelliculosa 44 (6.2) 0.15 0.02
C. glabrata 35 (4.9) 0.12 0.02
C. guilliermondii 17 (2.4) 0.06 0.009
P. ohmeri 9 (1.3) 0.03 0.005
C. krusei 8 (1.1) 0.03 0.004
Othersa 13 (1.3)
a Other Candida species: C. lusitaniae, four cases; C. lipolytica, three cases; C.
zeylanoides, one case; Candida sp., five cases.
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(0.17 per 1,000 admissions) (43), Norway (0.17 per 1,000 ad-
missions) (45), Hungary (0.20 to 0.40 per 1,000 admissions)
(14), Switzerland (0.27 per 1,000 admissions) (28), Italy (0.38
per 1,000 admissions) (49), and Spain (0.76 to 0.81 per 1,000
admissions) (4, 52). A similarly high incidence rate of candi-
demia (2.88 cases per 1,000 discharges) was reported in a
single-center study conducted in Taiwan (19). Although the
reasons for our high candidemia rates are not entirely clear, it
is possible that this may be related to a combination of multiple
factors, including differences in resources available for medical
care and training programs, difficulties in the implementation
of infection control programs in hospitals of developing coun-
tries, limited number of health care workers to assist patients
in critical care units, and less-aggressive practices of empirical
antifungal therapy and prophylaxis for high-risk patients. In-
deed, since our rates of BSI caused by other organisms are also
high, it seems that these factors may have affected not just
candidemia rates but the overall rates of BSI in Brazil.
The median age of our case patients was low (40 years)
compared to that reported in a series from the United States
(37). This is a reflection of a high proportion of children in our
study (32% compared to 9% in the study from the United
States), since the median age of our adults (57 years) was
similar to that reported in the American study (55 years). Most
of the children were premature babies (40%), but a large
proportion (41%) of the older children were in an ICU and
had cancer, neurologic disease, or lung disease. The adults with
candidemia comprised mostly case patients admitted to an
ICU (38%), with diseases such as diabetes, renal failure, car-
diac diseases and lung disease. Half of the ICU case patients
had surgery in the 30 days before candidemia, underscoring the
importance of surgical procedures and location in the ICU in
the epidemiology of candidemia (37, 50).
Over the past 10 years, some studies have reported a shift in
the etiology of candidemia. While C. albicans is still considered
the most common species causing candidemia, increasing rates
of candidemia caused by C. tropicalis, C. parapsilosis, C. gla-
brata, and C. krusei have been reported worldwide (11, 44, 51).
The reasons for the emergence of non-albicans species are not
completely understood, but some medical conditions may con-
sistently impact the risk of developing candidemia due to non-
albicans species: C. parapsilosis fungemia has been associated
with vascular catheters and parenteral nutrition (10, 17, 24), C.
tropicalis candidemia is associated with cancer and neutropenia
(23, 56), and C. krusei and C. glabrata fungemias are associated
with previous exposure to azoles (29, 51). The findings from
our surveillance are supportive of these reports.
Our series clearly consolidates the concept that candidemia
due to C. glabrata is rare in Brazil, and C. tropicalis and C.
parapsilosis account for the large majority (70%) of non-albi-
cans species. Why C. glabrata is unusual in Brazil is not clear,
but the wide geographic variability of species distribution sug-
gests that factors other than the use of fluconazole may be
important, including demographic characteristics (older age)
TABLE 3. Antifungal susceptibility test results for selected species of Candida isolated during prospective,
sentinel surveillance in Brazil in 2003 and 2004
Species (na) Antifungal agent
MIC (g/ml) % Resistantb
(no. of isolates)Range 50% 90%
C. albicans (291) Amphotericin B 0.125–1.0 0.5 1.0 0
Fluconazole 0.125–64 0.25 0.5 0.3 (1)
Itraconazole 0.03–1.0 0.03 0.03 0.3 (1)
5-Flucytosine 0.125–64 0.25 2.0 0.3 (1)
Voriconazole 0.03–4.0 0.03 0.03 0.3 (1)
C. tropicalis (149) Amphotericin B 0.125–1.0 0.5 1.0 0
Fluconazole 0.125–32 0.5 1.0 0
Itraconazole 0.03–0.25 0.03 0.125 0
5-Flucytosine 0.05–64 0.25 1.0 3 (5)
Voriconazole 0.03–0.5 0.03 0.06 0
C. parapsilosis (146) Amphotericin B 0.25–1.0 1.0 1.0 0
Fluconazole 0.125–8.0 1.0 4.0 0
Itraconazole 0.03–0.5 0.03 0.125 0
5-Flucytosine 0.125–64 0.25 0.5 1.4 (2)
Voriconazole 0.03–0.25 0.03 0.06 0
C. pelliculosa (44) Amphotericin B 0.125–2.0 0.25 0.75 0
Fluconazole 0.5–16 4.0 8.0 0
Itraconazole 0.03–0.5 0.125 0.5 0
5-Flucytosine 0.125–16 0.125 0.125 0
Voriconazole 0.03–0.25 0.06 0.25 0
C. glabrata (35) Amphotericin B 0.25–1.0 0.5 1.0 0
Fluconazole 2.0–64 8.0 32 6 (2)
Itraconazole 0.03–32 0.25 4 34 (12)
5-Flucytosine 0.125–8.0 0.125 0.25 0
Voriconazole 0.03–2.0 0.125 1.0 0
a n, no. of isolates.
b Resistance breakpoints: fluconazole, MIC of 64 g/ml; itraconazole, 1 g/ml; flucytosine, 32 g/ml; amphotericin B, 2 g/ml; voriconazole, 4 g/ml.
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(13) and the use of antibiotics (25). However, although the
proportion of C. glabrata in Brazil is low, the burden of C.
glabrata candidemia (0.12 cases per 1,000 admissions) is similar
to rates reported in other series (4).
In contrast, we report a high proportion of C. tropicalis
(21%) candidemia, even in neonates. European and North
American series have consistently reported low proportions of
C. tropicalis candidemia (2 to 10% in Europe and 10 to 12% in
the United States and Canada) (3, 4, 6, 13, 16, 22, 26, 28, 30, 37,
42, 47, 50, 51), whereas higher proportions were observed in a
study from Saudi Arabia (20.7%) (1). In our study, the pro-
portion varied from 16 to 29% among the different centers. We
were unable to determine any special distinguishing features
between centers with lower and higher proportions.
Like that with C. tropicalis, C. parapsilosis candidemia was
frequent in the present study, with a slightly lower proportion
than in our previous study (20.5% versus 25%) (11). There is
a wide variation in the proportion of C. parapsilosis as the
cause of candidemia in different series, with rates varying be-
tween 7 and 21% in the United States (13, 22) and 6.9 and 30%
in Europe (50). The reasons for these wide variations are not
clear but may be related to the proportion of neonates in each
study, as well as other local epidemiologic factors of this spe-
cies, since C. parapsilosis candidemia is thought to be acquired
from an external source (54).
We also observed a high proportion of candidemia caused by
C. pelliculosa, the asexual form of Pichia anomala. C. pellicu-
losa has rarely been reported as a cause of candidemia outside
of outbreaks, two of which occurred in Brazil (38, 48). Twenty-
nine of our C. pelliculosa isolates were from a single institution,
highlighting the possibility that this species may be associated
with nosocomial outbreaks. However, further investigation is
needed to understand the epidemiology of this cluster and to
determine factors associated with C. pelliculosa infection.
Antifungal resistance was a rare finding in our study and was
restricted to a few isolates. As with two recently published
studies (3, 36), none of our Candida bloodstream isolates had
MICs of 2 g/ml for amphotericin B. Our proportion of
fluconazole-susceptible C. glabrata isolates (51%) was some-
what lower than a report from other countries (62 to 81%)
(40). However, the percentage of fluconazole-resistant iso-
lates (5.7%) was similar to the rate observed with European
isolates (5.2%) and lower than that with North American
isolates (10.2%).
As reported by other authors (29), we also observed that
previous exposure to fluconazole was a strong and independent
factor associated with candidemia caused by fluconazole-non-
susceptible isolates. In addition, we observed that higher vori-
conazole MICs tended to be associated with prior exposure to
fluconazole. This is of concern and illustrates the potential
problem of cross-resistance between azoles. In another study
with 46 fluconazole-resistant C. glabrata isolates, only 13%
were susceptible to voriconazole, 4% to posaconazole, and
8.7% to ravuconazole (40). The potential for voriconazole-
resistant C. glabrata to emerge as a threat in people receiving
voriconazole therapy has been raised in two reports of break-
through infections (2, 20). Nevertheless, in our study, voricon-
azole was the azole which exhibited the best in vitro antifungal
activity, and only one of six fluconazole-resistant isolates was
cross-resistant to voriconazole.
The 30-day crude mortality rate observed in our study was
similar to that reported in our previous study (11), as well as by
other authors (3, 11, 18, 27). Younger children and adults had
higher mortality rates than children with ages between 1 and 12
years. Similar to other reports, patients with C. parapsilosis
candidemia had the lowest death rates (35, 37).
These comprehensive data document important differences
in the epidemiology of candidemia in Brazil compared to re-
ports from other countries. This report shows that candidemia
is a significant source of morbidity in Brazil, with a substantial
burden of disease, mortality, and likely high associated costs.
Although our high rates of candidemia may be related to high
rates of BSI in general in Brazilian public hospitals, reasons for
these high rates are not clear and warrant further study. De-
termining factors associated with these high rates may lead to
identifying measures that can help prevent disease. In addition,
our data support that fluconazole nonsusceptibility is associ-
ated with prior fluconazole exposure and suggest that such
exposure may lead to voriconazole cross-resistance.
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